<DOC>
	<DOCNO>NCT00500318</DOCNO>
	<brief_summary>This study evaluate effect inhaled aclidinium bromide exercise endurance reduce rest dynamic lung hyperinflation patient moderate severe COPD . It 9 week duration , consist ; 2-week run-in period , 6 week double-blind treatment , 1-week follow-up phone call . All patient meet eligibility criterion randomize one two treatment group : aclidinium bromide placebo .</brief_summary>
	<brief_title>A Study Exercise Endurance Lung Hyperinflation Patients With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>A diagnosis stable moderate severe COPD ( GOLD 2006 ) ; postlevalbuterol FEV1 &gt; =30 % &lt; 80 % predict FEV1/FVC &lt; 70 % predict Current former cigarette smoker Functional Residual Capacity ( FRC ) measure body plethysmography &gt; = 120 % predict value Baseline Dyspnea Index ( BDI ) focal score â‰¤ 7 Visit 4 History presence asthma , allergic rhinitis , atopy Hospitalization acute COPD exacerbation 3 month prior study entry Respiratory tract infection ( include upper respiratory tract ) COPD exacerbation 6 week prior study entry Clinically significant respiratory condition COPD Chronic use oxygen therapy &gt; = 15 hour day</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bronchitis , Chronic ; Emphysema</keyword>
</DOC>